IVADANTIN
LOE Approachingnitrofurantoin sodium
NDAINJECTIONINJECTABLE
Approved
Sep 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IVADANTIN is a nitrofurantoin sodium injectable formulation, a small-molecule antibiotic approved in 1960 for treating urinary tract infections via parenteral administration. It functions as a broad-spectrum antibacterial agent targeting gram-positive and gram-negative organisms in the urinary system.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team focus will likely shift toward lifecycle management and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IVADANTIN offers limited growth-stage career momentum but strong exposure to mature product lifecycle management, payer negotiation, and cost-containment strategy. This role suits professionals interested in operational excellence, healthcare economics, and legacy brand stewardship rather than innovation-focused advancement.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.